Search

Displaying results 661 - 670 of 7062 in total
  1. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success.

    Synonyms: Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through A protease cleavable valine-alanine linker
  2. Drug

    Niacin

    go.drugbank.com/drugs/DB00627
    ApprovedInvestigationalNutraceutical

    Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.

    Mixtures: Cda-21 Vitamins With Non-medicinal Probiotic Complex, Extra Once A DayCategories: Vitamin B Complex
  3. Drug

    Zinc

    go.drugbank.com/drugs/DB01593
    ApprovedInvestigational

    A metallic element of atomic number 30 and atomic weight 65.38. … It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division.

    Mixtures: One A Day Tab, Extra Once A DayProducts: Port A Mins Super Zinc 15, Port A Mins Super Zinc 30
  4. Drug

    Venlafaxine

    go.drugbank.com/drugs/DB00285
    ApprovedInvestigational

    Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). … It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).

    Products: VENLAVITAE® 75 MG CÁPSULAS DURAS DE LIBERACIÓN PROLONGADA, VENLAFAXIN 1A 75MG REK
  5. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601] … As a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects.

  6. Drug

    Benserazide

    go.drugbank.com/drugs/DB12783
    ApprovedInvestigational

    In particular, although the specific levodopa/benserazide combination is formally approved for use in Canada and much of Europe, the FDA has approved another similar levodopa/dopa decarboxylase inhibitor … Moreover, the European Medcines Agency has conferred an orphan designation upon benseraside since 2015 for its potential to be used as a therapy for beta thalassaemia as well [F3].

  7. Drug

    Allylestrenol

    go.drugbank.com/drugs/DB01431
    Investigational

    It is widely marketed throughout Europe, including Russia and many other European countries, and is also available in Japan, Hong Kong, India, Bangladesh, Indonesia, and much of Southeast Asia, though … A synthetic steroid with progestational activity.

  8. Drug

    Peginterferon alfa-2a

    go.drugbank.com/drugs/DB00008
    ApprovedInvestigational

    -2a for the treatment of Hepatitis C [A19593]. … Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C.

    Synonyms: PEG-IFN alfa-2A, PEG-Interferon alfa-2ACategories: peginterferon alfa-2a, peginterferon alfa-2a, combinations
  9. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. … As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent.

  10. Drug

    (+)-Mefloquine

    go.drugbank.com/drugs/DB05636
    Investigational

    compare the efficacy of (+) Mefloquine vs. racemic [Mefloquine]. … (+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to